GlobeNewswire 07/03/2025 argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the A...
GlobeNewswire 27/02/2025 argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
GlobeNewswire 25/02/2025 argenx to Present at TD Cowen 45th Annual Healthcare Conference
GlobeNewswire 20/02/2025 argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27,...
GlobeNewswire 28/08/2024 argenx to Present at Upcoming Investor Conferences
GlobeNewswire 26/08/2024 MDA Kicks Off Muscular Dystrophy Awareness Month in September with ‘30 Days of Strength’ Campaign wi...
GlobeNewswire 12/08/2024 Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
GlobeNewswire 25/07/2024 argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
GlobeNewswire 18/07/2024 argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 202...
GlobeNewswire 16/07/2024 argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Ge...
GlobeNewswire 08/07/2024 Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors
GlobeNewswire 25/06/2024 argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 P...
GlobeNewswire 21/06/2024 argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropat...
GlobeNewswire 17/06/2024 argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcomi...
GlobeNewswire 13/06/2024 Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
GlobeNewswire 04/06/2024 argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire 09/05/2024 argenx Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 07/05/2024 argenx announces results of Annual General Meeting of Shareholders
GlobeNewswire 07/05/2024 argenx to Present at BofA Securities 2024 Health Care Conference
GlobeNewswire 02/05/2024 argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
GlobeNewswire 16/04/2024 argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Pa...
GlobeNewswire 27/03/2024 argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
GlobeNewswire 26/03/2024 argenx Announces Annual General Meeting of Shareholders on May 7, 2024
GlobeNewswire 26/03/2024 argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thr...
GlobeNewswire 07/03/2024 argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of ...